These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 7852189)
21. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173 [TBL] [Abstract][Full Text] [Related]
22. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750 [TBL] [Abstract][Full Text] [Related]
23. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218 [TBL] [Abstract][Full Text] [Related]
24. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Fujita M; Enomoto T; Haba T; Nakashima R; Sasaki M; Yoshino K; Wada H; Buzard GS; Matsuzaki N; Wakasa K; Murata Y Int J Cancer; 1997 Apr; 74(2):148-55. PubMed ID: 9133447 [TBL] [Abstract][Full Text] [Related]
25. p53 mutation is infrequent in clear cell carcinoma of the ovary. Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858 [TBL] [Abstract][Full Text] [Related]
26. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Mandai M; Konishi I; Kuroda H; Komatsu T; Yamamoto S; Nanbu K; Matsushita K; Fukumoto M; Yamabe H; Mori T Hum Pathol; 1998 Jan; 29(1):34-40. PubMed ID: 9445131 [TBL] [Abstract][Full Text] [Related]
27. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado. Enomoto T; Fujita M; Inoue M; Nomura T; Shroyer KR Am J Clin Pathol; 1995 Feb; 103(2):224-30. PubMed ID: 7856567 [TBL] [Abstract][Full Text] [Related]
28. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors? Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961 [TBL] [Abstract][Full Text] [Related]
29. Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. Stemke-Hale K; Shipman K; Kitsou-Mylona I; de Castro DG; Hird V; Brown R; Flanagan J; Gabra H; Mills GB; Agarwal R; El-Bahrawy M Mod Pathol; 2013 Apr; 26(4):544-52. PubMed ID: 23174937 [TBL] [Abstract][Full Text] [Related]
30. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy. Diebold J; Seemüller F; Löhrs U Lab Invest; 2003 Feb; 83(2):251-8. PubMed ID: 12594239 [TBL] [Abstract][Full Text] [Related]
31. [Alterations of p53 gene in human ovarian tumor]. Chen P; Zhang Z; Zhang Q; Wu Y Hunan Yi Ke Da Xue Xue Bao; 1997; 22(5):401-3. PubMed ID: 10073019 [TBL] [Abstract][Full Text] [Related]
32. P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. Mueller J; Gansauge S; Mattfeldt T Hepatogastroenterology; 2003; 50(50):541-4. PubMed ID: 12749268 [TBL] [Abstract][Full Text] [Related]
33. [K-ras mutation analysis in ovarian serous borderline and malignant tumors]. Ma L; Guo LN; Liang ZY; Ren XY; Wu SF Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):714-8. PubMed ID: 17374253 [TBL] [Abstract][Full Text] [Related]
34. [Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer]. Guan X; Lang J; Bian M Zhonghua Fu Chan Ke Za Zhi; 1998 Mar; 33(3):165-7. PubMed ID: 10682487 [TBL] [Abstract][Full Text] [Related]
35. Detection of K-ras and p53 gene mutations in pancreatic juice for the diagnosis of intraductal papillary mucinous tumors. Kaino M; Kondoh S; Okita S; Hatano S; Shiraishi K; Kaino S; Okita K Pancreas; 1999 Apr; 18(3):294-9. PubMed ID: 10206488 [TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Pieretti M; Hopenhayn-Rich C; Khattar NH; Cao Y; Huang B; Tucker TC Cancer Invest; 2002; 20(1):11-23. PubMed ID: 11852993 [TBL] [Abstract][Full Text] [Related]
37. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy. Bar JK; Harłozińska A; Popiela A; Noga L Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280 [TBL] [Abstract][Full Text] [Related]
38. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors. Jamieson S; Alexiadis M; Fuller PJ Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971 [TBL] [Abstract][Full Text] [Related]
39. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cuatrecasas M; Erill N; Musulen E; Costa I; Matias-Guiu X; Prat J Cancer; 1998 Mar; 82(6):1088-95. PubMed ID: 9506354 [TBL] [Abstract][Full Text] [Related]
40. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]